Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism

Molecular Cancer Therapeutics

Volumn 8, Issue 9, 2009, Pages 2575-2585

  Elrod, Heath A ^a   Yue, Ping ^a   Khuri, Fadlo R ^a   Sun, Shi Yong ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; COMPLEMENTARY RNA; CYCLOOXYGENASE 2; PERIFOSINE; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CELL CYCLE ARREST; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG ANTAGONISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CYCLOOXYGENASE 2; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; PHOSPHORYLCHOLINE; PYRAZOLES; RNA, SMALL INTERFERING; SULFONAMIDES;

EID: 70349484470     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0390     Document Type: Article

References (39)

1. Ruiter GA, Verheij M, Zerp SF, van Blitterswijk WJ. Alkyl- lysophospholipids as anticancer agents and enhancers of radiation-induced apoptosis. Int J Radiat Oncol Biol Phys 2001;49:415-419 (Pubitemid 32120238)
2. Jendrossek V, Handrick R. Membrane targeted anticancer drugs: potent inducers of apoptosis and putative radiosensitisers. Curr Med Chem Anticancer Agents 2003;3:343-353
3. Hilgard P, Klenner T, Stekar J, Nossner G, Kutscher B, Engel J. D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur J Cancer 1997;33:442-446 (Pubitemid 27168072)
4. Dasmahapatra GP, Didolkar P, Alley MC, Ghosh S, Sausville EA, Roy KK. In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines. Clin Cancer Res 2004;10:5242-5252
5. Rahmani M, Reese E, Dai Y, et al. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res 2005;65:2422-2432 (Pubitemid 40490154)
6. Nyakern M, Cappellini A, Mantovani I, Martelli AM. Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Mol Cancer Ther 2006;5:1559-1570 (Pubitemid 44070493)
7. Li X, Luwor R, Lu Y, Liang K, Fan Z. Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells. Oncogene 2006;25:525-535 (Pubitemid 43164463)
8. Stephenson J, Schreeder M, Waples J, et al. Perifosien (P), active as a single agent for renal cell carcinoma (RCC), now in phase I trials combined with tryosine kinase inhibitors (TKI). J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I 2007;25:15622.
9. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003;2:1093-1103
10. Patel V, Lahusen T, Sy T, Sausville EA, Gutkind JS, Senderowicz AM. Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading tolo ss in cyclin-dependent kinase activity and cell cycle arrest. Cancer Res 2002;62:1401-1409 (Pubitemid 34407799)
11. Elrod HA, Lin YD, Yue P, et al. The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol Cancer Ther 2007;6:2029-2038 (Pubitemid 47052493)
12. Frampton JE, Keating GM. Celecoxib: a review of its use in the management of arthritis and acute pain. Drugs 2007;67:2433-2472 (Pubitemid 350080285)
13. Koki AT, Masferrer JL. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control 2002;9:28-35. (Pubitemid 34457338)
14. Grosch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006;98:736-747 (Pubitemid 43983297)
15. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM. Cyclooxygenases in cancer: progress and perspective. Cancer Lett 2004;215:1-20.
16. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003;4:431-436 (Pubitemid 38050040)
17. Bol DK, Rowley RB, Ho CP, et al. Cyclooxygenase-2 overexpression in the skin of transgenic mice results in suppression of tumor development. Cancer Res 2002;62:2516-2521
18. Yegnasubramanian S, Kowalski J, Gonzalgo ML, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004;64:1975-1986 (Pubitemid 38339443)
19. Nakopoulou L, Mylona E, Papadaki I, et al. Overexpression of cyclooxygenase-2 is associated with a favorable prognostic phenotype in breast carcinoma. Pathobiology 2005;72:241-249 (Pubitemid 43004467)
20. O'Kane SL, Cawkwell L, Campbell A, Lind MJ. Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma. Eur J Cancer 2005;41:1645-1648 (Pubitemid 40981848)
21. Trifan OC, Smith RM, Thompson BD, Hla T. Overexpression of cyclooxygenase-2 induces cell cycle arrest. Evidence for a prostaglandin- independent mechanism. J Biol Chem 1999;274:34141-34147 (Pubitemid 129511751)
22. Xu Z, Choudhary S, Voznesensky O, et al. Overexpression of COX-2 in human osteosarcoma cells decreases proliferation and increases apoptosis. Cancer Res 2006;66:6657-6664 (Pubitemid 44085622)
23. Tang HY, Shih A, Cao HJ, Davis FB, Davis PJ, Lin HY. Resveratrol-induced cyclooxygenase-2 facilitates p53-dependent apoptosis in human breast cancer cells. Mol Cancer Ther 2006;5:2034-2042 (Pubitemid 44336575)
24. Hinz B, Ramer R, Eichele K, Weinzierl U, Brune K. Up-regulation of cyclooxygenase-2 expression is involved in R(+)-methanandamide-induced apoptotic death of human neuroglioma cells. Mol Pharmacol 2004;66:1643-1651 (Pubitemid 39564792)
25. Davaille J, Gallois C, Habib A, et al. Antiproliferative properties of sphingosine 1-phosphate in human hepatic myofibroblasts. A cyclooxygenase-2 mediated pathway. J Biol Chem 2000;275:34628-34633 (Pubitemid 30819240)
26. Eichele K, Ramer R, Hinz B. Decisive role of cyclooxygenase-2 and lipocalin-type prostaglandin D synthase in chemotherapeutics-induced apoptosis of human cervical carcinoma cells. Oncogene 2008;27:3032-3044 (Pubitemid 351668009)
27. Lin HY, Tang HY, Keating T, et al. Resveratrol is pro-apoptotic and thyroid hormone is anti-apoptotic in glioma cells: both actions are integrin and ERK mediated. Carcinogenesis 2008;29:62-69 (Pubitemid 351201742)
28. Na HK, Inoue H, Surh YJ. ET-18-O-CH3-induced apoptosis is causally linked to COX-2 upregulation in H-ras transformed human breast epithelial cells. FEBS Lett 2005;579:6279-6287 (Pubitemid 41546279)
29. Kardosh A, Soriano N, Liu YT, et al. Multitarget inhibition of drugresistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib. Blood 2005;106:4330-4338 (Pubitemid 41775944)
30. Sun SY, Yue P, Dawson MI, et al. Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human nonsmall cell lung carcinoma cells. Cancer Res 1997;57:4931-4939 (Pubitemid 27469005)
31. Krysan K, Merchant FH, Zhu L, et al. COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J 2004;18:206-208
32. Zhang X, Su L, Pirani AA, et al. Understanding metastatic SCCHN cells from unique genotypes to phenotypes with the aid of an animal model and DNA microarray analysis. Clin Exp Metastasis 2006;23:209-222 (Pubitemid 44673810)
33. Liu X, Yue P, Zhou Z, Khuri FR, Sun SY. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst 2004;96:1769-1780 (Pubitemid 39654571)
34. Sun SY, Yue P, Wu GS, et al. Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells. Oncogene 1999;18:2357-2365 (Pubitemid 29192713)
35. Momota H, Nerio E, Holland EC. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res 2005;65:7429-7435 (Pubitemid 41161277)
36. Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006;107:4053-4062 (Pubitemid 43726814)
37. Na HK, Surh YJ. Induction of cyclooxygenase-2 in Ras-transformed human mammary epithelial cells undergoing apoptosis. Ann N Y Acad Sci 2002;973:153-160 (Pubitemid 36124997)
38. Straus DS, Glass CK. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev 2001;21:185-210.
39. Niederberger E, Tegeder I, Vetter G, et al. Celecoxib loses its antiinflammatory efficacy at high doses through activation of NF-κB. FASEB J 2001;15:1622-1624